To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase).
To evaluate the safety of Diamyd® 20ug.
10 Years to 18 Years (Child, Adult)
D/P2/04/3 EUDRACT 2004-003764-30
February 16, 2007
January 30, 2008
Borås Hospital Borås, Sweden
The Queen Silvia Children´s Hospital Göteborg, Sweden
Halmstad Hospital Halmstad, Sweden
(and 5 more...)
† Study has passed its completion date and status has not been verified in more than two years.